This module will cover the key basics of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and the role of HSCT in treating hematologic malignancies and select solid tumors. Topics covered will include stem cell source, mobilization, conditioning regimen intensity and agents utilized, and management of short and long-term complications including graft-versus-host disease (GVHD), infectious complications, and adverse effects of chemotherapy. The role of haploidentical HSCT, outpatient HSCT management, novel agents for GVHD treatment and infection prophylaxis, and the role of post-HSCT maintenance therapy will be highlighted given the increasing use in practice and recent FDA approvals.
- Distinguish the differences between available donor types, stem cell sources, and conditioning regimen intensity used in HSCT
- Identify dose‐limiting toxicities associated with HSCT conditioning regimens and appropriate management strategies
- Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the prevention and management of acute graft-versus-host disease (GVHD), chronic GVHD, and infections typically observed in the HSCT population
Speaker: Katie Gatwood, PharmD, BCOP
Disclosures: Jazz Pharmaceuticals, Consultant/Advisory Board, Speaker/Honoraria; Kite/Gilead, Speaker/Honoraria; Sanofi, Speaker/Honoraria; American Society for Blood and Marrow Transplantation Pharmacy SIG, Steering Committee member; American College of Clinical Pharmacy - Hematology/Oncology PRN, Membership & Operations Committee member
Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.
Activity Type: Application